Matinas BioPharma (MTNB) Stock Price, News & Analysis

Company Overview

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy. It also offers MAT2501, an orally administered formulation of amikacin to treat chronic and acute bacterial infections, as well as non-tuberculosis mycobacterium. The company has strategic collaborations with the National Institute of Allergy and Infectious Diseases for the development of oral formulations of Gilead's remdesivir; BioNTech SE to evaluate the combination of mRNA formats with the LNC platform; and Genentech Inc. to develop oral formulations. Matinas BioPharma Holdings, Inc. was incorporated in 2013 and is based in Bedminster, New Jersey.

Key Stats

• Today's Range: $0.54 to $0.98
• 50-Day Range: N/A
• 52-Week Range: $0.54 to $21.50
• Volume: 3.04 million shs
• Average Volume: 45,152 shs
• Market Capitalization: $3.11 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Matinas BioPharma Stock Analysis - MarketRank™

Matinas BioPharma scored higher than 4% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Matinas BioPharma.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Matinas BioPharma is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Matinas BioPharma is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Matinas BioPharma has a P/B Ratio of 0.14. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.64% of the float of Matinas BioPharma has been sold short.

Short Interest Ratio / Days to Cover

Matinas BioPharma has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Matinas BioPharma has recently increased by 28.23%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Matinas BioPharma does not currently pay a dividend.

Dividend Growth

Matinas BioPharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.64% of the float of Matinas BioPharma has been sold short.

Short Interest Ratio / Days to Cover

Matinas BioPharma has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Matinas BioPharma has recently increased by 28.23%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.0 / 5
• News Sentiment: -0.20

News Sentiment

Matinas BioPharma has a news sentiment score of -0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Matinas BioPharma this week, compared to 1 article on an average week.

Search Interest

Only 2 people have searched for MTNB on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Matinas BioPharma to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Matinas BioPharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 9.60% of the stock of Matinas BioPharma is held by insiders.

Percentage Held by Institutions

Only 11.77% of the stock of Matinas BioPharma is held by institutions.

MTNB Stock Analysis - Frequently Asked Questions

How have MTNB shares performed this year?

Matinas BioPharma's stock was trading at $0.2801 at the start of the year. Since then, MTNB stock has increased by 121.3% and is now trading at $0.62.
View the best growth stocks for 2024 here.

How were Matinas BioPharma's earnings last quarter?

Matinas BioPharma Holdings, Inc. (NYSEAMERICAN:MTNB) released its quarterly earnings data on Wednesday, August, 14th. The company reported ($0.02) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.02).

How do I buy shares of Matinas BioPharma?

Shares of MTNB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Matinas BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Matinas BioPharma investors own include Acasti Pharma (ACST), SCYNEXIS (SCYX), Tesla (TSLA), Corbus Pharmaceuticals (CRBP), Viking Therapeutics (VKTX), Sorrento Therapeutics (SRNE) and TherapeuticsMD (TXMD).

Company Calendar

• Last Earnings: 8/14/2024
• Today: 10/31/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSEAMERICAN:MTNB
• CUSIP: N/A
• CIK: N/A
• Web: www.matinasbiopharma.com
• Phone: (908) 484-8805
• Fax: N/A
• Employees: 32
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($5.50)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-22,940,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -120.50%
• Return on Assets: -92.69%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.39
• Quick Ratio: 6.39

Sales & Book Value

• Annual Sales: $1.10 million
• Price / Sales: 2.83
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.43 per share
• Price / Book: 0.14

Miscellaneous

• Outstanding Shares: 5,020,000
• Free Float: 4,534,000
• Market Cap: $3.11 million
• Optionable: Not Optionable
• Beta: 1.64